Welcome to the CJU website » LOG IN


Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence
Department of Surgery, University of Toronto, Sunnybrook Health Science Center,
Sep  1996 (Vol.  3, Issue  3, Pages( 246 - 250)


Text-Size + 

  • The conflicting data surrounding the benefit of total androgen blockade compared to monotherapy for metastatic prostate cancer is reviewed. The recent Lancet meta-analysis is critically appraised. A sensitivity analysis of the studies is presented.